Table 1.
Antiangiogenic compounds currently approved by the USA Food and Drug Administration (FDA).
| Drug Name (Commercial) | Cancer Type (Recommended Use) | Main Mechanism of Action |
|---|---|---|
| Bevacizumab (Avastin) | Metastatic colorectal | VEGF antibody |
| Renal cell carcinoma (RCC) | ||
| Non-small cell lung cancer (NSCLC) | ||
| Ovarian | ||
| Ramucirumab (Cyramza) | Advanced stomach | VEGFR2 antibody |
| Gastroesophageal adenocarcinoma | ||
| NSCLC | ||
| Metastatic colorectal | ||
| Cetuximab (Erbitux) | CRC | EGFR antibody |
| Head and neck squamous cell carcinoma | ||
| NSCLC | ||
| Panitumumab (Vectibix) | CRC | EGFR antibody |
| Trastuzumab (Herceptin) | HER2+ breast cancer | EGFR antibody |
| Aflibercept (Zaltrap or Eylea) | Colorectal cancer (CRC) | VEGF-trap * |
| Sunitinib (Sotent) | RCC | TKI |
| Pancreatic neuroendocrine tumors (PNETs) | ||
| Gastrointestinal stromal tumors (GISTs) | ||
| Axitinib (Inlyta) | RCC | TKI |
| Vandetanib (Caprelsa) | Medullary carcinoma of thyroid | TKI |
| Lenvatinib (Lenvima) | Thyroid | TKI |
| Pazopanib (Votrient) | RCC | TKI |
| Soft tissue sarcoma | ||
| Cabozantinib (Cometriq) | Medullary thyroid cancer | TKI |
| Erlotinib (Tarceva) | Pancreatic cancer | TKI |
| Gefitinib (Iressa) | Lung cancer | TKI |
| Breast cancer | ||
| Imatinib (Glivec) | Chronic myeloid leukemia | TKI |
| Acute lymphoid leukemia | ||
| GISTs | ||
| Lapatinib (Tyverb) | HER2+ breast cancer | TKI |
| Sorafenib (Nexavar) | Hepatocellular carcinoma | TKI |
| RCC | ||
| Thyroid | ||
| Regorafenib (Stivarga) | Refractory metastatic colorectal | TKI |
| Advanced GISTs | ||
| Thalidomide (Thalomid) | Multiple myeloma | Immunomodulator |
| Lenalidomide (Revlimid) | Multiple myeloma | Immunomodulator |
| Non-Hodgkin lymphoma | ||
| Rapamycin (Sirolimus) | RCC | mTOR inhibitor |
| Temsirolimus (Torisel) | RCC | mTOR inhibitor |
| Everolimus (Afinitor) | RCC | mTOR inhibitor |
| Advanced breast | ||
| PNETs |
Abbreviations: TKI, tyrosine kinase inhibitor; mTOR, mammalian target of rapamycin. * For a full description of VEGF-trap see text.